

1 **Post COVID-19 Condition, Work Ability and Occupational Changes: Results from**  
2 **a Population-based Cohort**

3

4 Philipp Kerksieck<sup>1\*</sup>, Tala Ballouz<sup>1\*</sup>, Sarah R. Haile<sup>1</sup>, Celine Schumacher<sup>1</sup>, Joanne Lacy<sup>1</sup>, Anja  
5 Domenghino<sup>1,2</sup>, Jan S. Fehr<sup>1</sup>, Georg F. Bauer<sup>1</sup>, Holger Dressel<sup>1</sup>, Milo A. Puhan<sup>1†</sup>, Dominik Menges<sup>1</sup>

6

7 <sup>1</sup> *Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich (UZH), Zurich,*  
8 *Switzerland*

9 <sup>2</sup> *Department of Visceral and Transplantation Surgery, University Hospital Zurich (USZ), Zurich,*  
10 *Switzerland*

11 *\* These authors share first authorship due to equal contribution.*

12

13 † **Corresponding author:** Milo A. Puhan, Epidemiology, Biostatistics and Prevention Institute (EBPI),  
14 University of Zurich (UZH), Hirschengraben 84, CH-8001 Zurich, Switzerland, Phone: +41 44 634 46 10,  
15 Email: [miloalan.puhan@uzh.ch](mailto:miloalan.puhan@uzh.ch)

16

17 **Short Title:** Post COVID-19 Condition and Work Ability

18

19

20 **Abstract**

21 **Background:** Evidence from population-based studies on the impact of post COVID-19 condition (PCC)  
22 on ability to work is limited but critical due to its high prevalence among individuals of working-age.

23 **Objective:** To evaluate the association between PCC, work ability, and occupational changes.

24 **Design:** Population-based, longitudinal cohort.

25 **Setting:** General population, Canton of Zurich, Switzerland.

26 **Participants:** 672 adults of working-age with SARS-CoV-2 infection.

27 **Measurements:** Current work ability, work ability related to physical and mental demands, and estimated  
28 future work ability in 2 years (assessed using Work Ability Index), as well as PCC-related occupational  
29 changes at one year after infection.

30 **Results:** There was very strong evidence that current work ability scores were 0.62 (95% confidence  
31 interval (CI) 0.30 to 0.95) points lower among those with PCC compared to those without. Similarly, there  
32 was very strong evidence for lower odds of reporting higher work ability with respect to physical (odds  
33 ratio (OR) 0.30, 95% CI 0.20 to 0.46) and mental (OR 0.40, 0.27 to 0.62) demands among those with PCC  
34 compared to those without. Higher age and history of psychiatric diagnosis were associated with a more  
35 substantial reduction in current work ability. 5.8% of those with PCC reported direct effects of PCC on  
36 their occupational situation, with 1.6% of those with PCC completely dropping out of the workforce and  
37 43% of those with PCC-related occupational changes reporting financial difficulties as a result.

38 **Limitations:** Selection, use of self-reported outcome measures, and limited generalizability to individuals  
39 with most severe COVID-19 or following vaccination.

40 **Conclusions:** These findings highlight the need for providing support and interdisciplinary interventions  
41 to individuals affected by PCC to help them maintain or regain their work ability and productivity.

42 **Primary Funding Source:** Federal Office of Public Health, Department of Health of the Canton of Zurich,  
43 University of Zurich Foundation, Switzerland.

44 **Study Registration:** ISRCTN14990068.

45

## 46 **Introduction**

47 Post COVID-19 condition (PCC) affects 10-20% of individuals infected with SARS-CoV-2 (1–11).  
48 Symptoms associated with PCC are varied and can be physical (e.g., fatigue, post-exertional malaise, pain,  
49 and dyspnea) or mental (most commonly memory and concentration difficulties) (2,12,13). Many of these  
50 symptoms adversely impact individuals' everyday functioning, including impairments to their ability to  
51 engage in physical activities and participate in social life and work (1,2,14). The prevalence of PCC is  
52 highest among those of working age (11,12) and the resulting socioeconomic implications are likely  
53 considerable (15,16). While it is important to develop effective management strategies and interventions to  
54 reduce the health burden of PCC, it is thus critical to also consider its impact on the workforce and establish  
55 sensible pathways to restore occupational participation in those severely affected.

56

57 Few studies have evaluated the association of PCC with work-related functioning or subsequent  
58 occupational changes (17–27). Most focused on describing work absenteeism and found that 11%-50% of  
59 workers do not return to work several months after COVID-19 (2,14). Various individual, organizational,  
60 and systemic aspects (e.g., supportive return-to-work policies) contribute to successful return to work after  
61 an illness, including having sufficient actual work ability (28–30). Work ability is a multifactorial measure  
62 frequently used in clinical practice and research to assess the degree to which an individual is physically  
63 and mentally able to cope with demands at work (31–33). In addition to short- and long-term sickness  
64 absence (34–37), poor work ability is also associated with early retirement (38,39) and disability at work  
65 (39,40), all of which carry large repercussions for the labor market and economy. Rehabilitation programs  
66 targeted at the working-age population generally aim to improve or preserve work ability. Given the  
67 substantial prevalence of PCC and its potential for long-term work-related consequences, understanding  
68 the association of PCC with work ability is crucial for the development of policies and multidisciplinary  
69 strategies aimed at supporting affected individuals in their recovery.

70

71 In this study, we aimed to comprehensively evaluate the association between PCC, work ability, and  
72 occupational changes in a working-age population within a prospective population-based cohort of SARS-  
73 CoV-2 infected individuals.

74

## 75 **Methods**

### 76 **Study Design and Participants**

77 We used data from a population-based, prospective, observational cohort of individuals with diagnosed  
78 SARS-CoV-2 infection from the Canton of Zurich, Switzerland (Zurich SARS-CoV-2 Cohort;  
79 ISRCTN14990068) (41). Based on mandatory reporting of all SARS-CoV-2 infections to the Department  
80 of Health of the Canton of Zurich, we prospectively invited on a daily basis an age-stratified (18–39 years,  
81 40–64 years,  $\geq 65$  years), random sample of eligible individuals diagnosed between 06 August 2020 and 19  
82 January 2021 for study participation. Eligibility criteria were being 18 years or older, able to follow study  
83 procedures, residing in the Canton of Zurich, and having sufficient knowledge of the German language. All  
84 participants were enrolled upon or shortly after diagnosis, infected with wildtype SARS-CoV-2, and were  
85 unvaccinated at time of infection. In this study we included individuals of working age (18–64 years old;  
86 the retirement age is 65 years in Switzerland (42)) who did not report being retired at enrollment. To ensure  
87 that evaluated outcomes were not related to reinfection with SARS-CoV-2 over the course of follow-up,  
88 we excluded individuals reporting a reinfection event. The study was approved by the ethics committee of  
89 the Canton of Zurich (BASEC-Nr. 2020-01739) and we obtained written or electronic consent from all  
90 participants.

91

### 92 **Data Sources**

93 We collected data using electronic questionnaires. At baseline immediately after enrollment, we collected  
94 data on the acute primary infection (i.e., symptoms, severity), pre-existing comorbidities (any of  
95 hypertension, diabetes, cardiovascular disease, chronic respiratory disease, chronic kidney disease,  
96 malignancy, or immune suppression), pre-infection health status, and socio-demographic characteristics. In  
97 this ongoing cohort, we collect follow-up data on participants' health trajectories in regular intervals after  
98 infection (9,10). At 12 months, we additionally elicited measures of work ability and asked participants to  
99 report any occupational changes over the first 12 months post-infection. Simultaneously, we asked  
100 participants to report any pre-existing psychiatric diagnoses before infection and any new or worsened  
101 psychiatric diagnoses during follow-up. Participants were also asked to provide further details in free text  
102 fields. One researcher (DM) additionally conducted personal phone interviews with participants for whom  
103 questionnaire information was not unequivocal (n=4).

104

## 105 **Outcome Measurement**

106 We assessed self-perceived work ability using selected measures from the Work Ability Index, a validated  
107 and frequently used instrument for assessing work ability (31,32,34). The primary outcome was the current  
108 work ability scale (score from 1–10, with 10 being best ability and 0 no ability to work). In sensitivity  
109 analyses, we categorized current work ability into poor (scores  $\leq 6$ ), moderate (scores 7-8), and excellent  
110 (scores  $\geq 9$ ) (43). Secondary outcomes included items evaluating work ability related to physical and mental  
111 demands (5-point Likert scale) and estimated future work ability in 2 years (3-point Likert scale), and  
112 occupational changes related to PCC during follow-up. We defined PCC using two different measures.  
113 First, we defined the presence of PCC as participants (self-)reporting any COVID-19 related symptom out  
114 of a list of 23 common PCC-related symptoms at 12 months of follow-up (*PCC status*). Second, we used a  
115 combined measure of whether participants had fully recovered and how they assessed their current health  
116 status (using the EuroQol visual analog scale (EQ-VAS)) at 12 months (*non-recovery and health*  
117 *impairment status*); non-recovered participants were categorized into mild (EQ-VAS  $>70$ ), moderate (EQ-  
118 VAS 51–70) and severe health impairment (EQ-VAS  $\leq 50$ ) based on population-normative values from  
119 previous research (10,44–46). Further measures indicating potential presence of PCC were individual  
120 COVID-19 related symptoms, commonly reported PCC-related symptom clusters (fatigue/physical  
121 exertion, cardiorespiratory (defined as dyspnea, palpitation, or chest pain), or neurocognitive (defined as  
122 concentration, memory, or sleeping problems)), EuroQol 5-dimension 5-level scale (EQ-5D-5L), Fatigue  
123 Assessment Scale (FAS), 21-item Depression, Anxiety and Stress Scale (DASS-21), and modified Medical  
124 Research Council (mMRC) dyspnea scale. Further information on evaluated work ability outcomes,  
125 occupational changes, and PCC-related outcomes is provided in Supplementary Table S1.

126

## 127 **Statistical Analysis**

128 We descriptively compared the reported work ability outcomes in individuals with PCC or reporting non-  
129 recovery with associated level of health impairment 12 months after diagnosis. We further descriptively  
130 analyzed differences between individuals reporting individual symptoms, symptom clusters, or problems  
131 in any of the standardized health assessments (EQ-5D-5L overall and subdomains, FAS, DASS-21, mMRC  
132 dyspnea scale) and those without. We then used multivariable regression models to evaluate the association

133 of PCC-related outcomes with work ability outcomes. Model selection included age, sex, baseline health  
134 status, hospitalization during acute infection as a priori covariates, with education level, comorbidity count,  
135 and history of psychiatric diagnosis added based on improved model fit using the Bayesian Information  
136 criterion (BIC; 2-point change considered relevant). For current work ability, we used linear regression  
137 (scores 1–10) in primary and ordinal logistic regression (poor, moderate, excellent work ability) in  
138 sensitivity analyses. We used ordinal logistic regression for Likert scale-based work ability outcomes.  
139 Correspondingly, we report adjusted linear model estimates and odds ratios (ORs) with corresponding 95%  
140 confidence intervals (CIs). We evaluated differences in the strength of association (i.e., effect modification)  
141 between participant subgroups based on sex (male vs. female), age (40–64 years vs. 18–39 years),  
142 comorbidity count (0–1 comorbidity vs.  $\geq 2$  comorbidities), and history of psychiatric diagnosis (present vs.  
143 absent), descriptively and by using interaction models. Additionally, we descriptively analyzed differences  
144 in work ability based on the occurrence of new or worsened psychiatric diagnoses. And last, we described  
145 the occupational changes by participants overall and specifically related to PCC. We performed all  
146 statistical analyses using R (v4.2.2) (47).

147

## 148 **Results**

### 149 **Participant Characteristics**

150 Of 1106 Zurich SARS-CoV-2 Cohort participants, 306 were not part of the working-age population, 15  
151 were excluded due to reinfection, and 113 did not provide data at 12 months (Figure 1). Of 672 participants,  
152 included in this study, 364 (54.2%) were female, 390 (58.0%) were aged 40–64 years, 79 (11.8%) were  
153 asymptomatic, and 9 (1.3%) were hospitalized at initial infection (Table 1). 19 participants (2.8%) reported  
154 being unemployed and 4 (0.6%) reported receiving disability insurance benefits at baseline. There were  
155 differences in age, sex, severity of acute infection, comorbidities, and history of psychiatric diagnoses  
156 between those categorized as having PCC and those without (Supplementary Table S2).

157

### 158 **Work Ability**

159 In descriptive analyses of current work ability, ability related to physical and mental demands at work, and  
160 estimated future work ability in 2 years, there was a relevant reduction in work ability across all four  
161 outcomes among those with PCC (based on reporting COVID-19 related symptoms) compared to those

162 without and among those reporting non-recovery compared to those that had recovered at 12 months (Figure  
163 2, Supplementary Table S3). Work ability among those reporting non-recovery was more strongly reduced  
164 in those with moderate and severe health impairment compared to those with mild health impairment.

165

166 In adjusted regression analyses, there was very strong evidence that current work ability scores were 0.62  
167 (95% CI 0.30 to 0.95) points lower among those with PCC compared to those without (Figure 3). Current  
168 work ability scores were 0.55 (0.21 to 0.88), 3.37 (2.58 to 4.16), and 5.10 (4.16 to 6.04) points lower among  
169 those with non-recovery and mild, moderate, and severe health impairment, respectively, compared to those  
170 reporting full recovery (very strong evidence). Similarly, there was very strong evidence for a lower odds  
171 of having higher work ability with respect to physical (OR 0.30, 95% CI 0.20 to 0.46) and mental (OR 0.40,  
172 0.27 to 0.62) demands among those with PCC compared to those without. Results were similar when  
173 evaluating non-recovered individuals compared to those reporting recovery, while reductions in work  
174 ability were more pronounced with higher levels of health impairment. There was no evidence for lower  
175 odds of having higher estimated future work ability in 2 years (OR 0.52, 0.26 to 1.06) among those with  
176 PCC compared to those without and among those with non-recovery and mild health impairment compared  
177 to those reporting recovery, but very strong evidence for a reduction in those with moderate or severe health  
178 impairment compared to recovered participants. Sensitivity analyses treating current work ability as an  
179 ordinal outcome showed similar results (Supplementary Figure S1).

180

181 Further analyses demonstrate the association between the presence of specific symptom clusters, individual  
182 COVID-19 related symptoms, and presence of health problems in EQ-5D-5L, FAS, DASS-21, and mMRC  
183 dyspnea scale and current work ability at 12 months (Supplementary Figures S2–S4, Supplementary Tables  
184 S4–S8). Across these analyses, there was very strong evidence for an association between most of the  
185 outcomes and current work ability, although not for all individual symptoms.

186

### 187 **Work Ability in Participant Subgroups**

188 In subgroup analyses, there was strong evidence for a difference in the association (i.e., effect modification)  
189 of PCC with current work ability and work ability related to physical demands between participants aged  
190 40–64 years and those aged 18–39 years, with a higher reduction in work ability in the older group (Table

191 2, Supplementary Tables S9–S12). Meanwhile, there was no evidence for a difference in the association of  
192 PCC with any work ability outcome between male and female participants, or between participants with 0–  
193 1 comorbidity and participants with  $\geq 2$  comorbidities. Last, there was a stronger association of PCC with  
194 current work ability (strong evidence) and work ability related to mental demands (weak evidence) in  
195 participants with history of psychiatric diagnosis compared to those without. Further descriptive analyses  
196 demonstrated relevant differences between participants with different mental health trajectories, indicating  
197 a stronger reduction in work ability among participants with history of psychiatric diagnosis and those with  
198 a new or worsened psychiatric diagnosis compared to those without history or new or worsened diagnosis,  
199 respectively (Supplementary Table S13).

200

### 201 **Occupational Changes**

202 When evaluating occupational changes up to 12 months, overall 119 (18.1%) participants reported to have  
203 had such a change during follow-up (Table 3), with a slightly higher proportion among participants with  
204 PCC (31/120, 25.8%) compared to those without PCC (88/552, 16.3%). 7 participants (1.1% of all  
205 participants, 5.8% of those with PCC) reported to have faced direct effects by PCC on their occupational  
206 situation. Work ability at 12 months was relevantly reduced among those 7 participants with occupational  
207 changes related to PCC compared to those without occupational changes and those with PCC-unrelated  
208 occupational changes (Supplementary Table S14).

209

210 The 7 participants with PCC-related occupational changes reported various individual stories in how PCC  
211 affected their work life. One participant lost their work due to PCC. Another reported to be on permanent  
212 sick leave at 12 months and being severely affected in daily life. One participant reported that they were  
213 unemployed at baseline and could not take on a new position due to PCC, and one was in a job re-integration  
214 program but was unable to re-enter the job market due to PCC. Another participant was so severely  
215 impacted cognitively that they could no longer use their professional skills (university level) and had to  
216 switch to doing simple administrative tasks. One health care worker reported that they had to take a different  
217 position that did not require working night shifts. And one participant reported that they had to discontinue  
218 their self-employed work as an instructor and seek another part-time job to cope financially because of



219 PCC. Overall, 3 participants (43%) with PCC-related occupational changes reported to have some financial  
220 difficulties as a result of their condition and their resulting occupational situation.

221

## 222 **Discussion**

### 223 **Main Findings in Context**

224 In this prospective population-based cohort of working-age individuals previously infected with SARS-  
225 CoV-2, we found that the presence of PCC was strongly associated with a reduction in work ability at 12  
226 months after diagnosis. Among non-recovered, higher levels of health impairment were also associated  
227 with substantially lower current work ability and work ability related to physical and mental demands. We  
228 found strong evidence that higher age and a history of psychiatric diagnosis was associated with a stronger  
229 reduction in current work ability. About 1 in 15 of those with PCC reported having had occupational  
230 changes due to PCC within one year, with 1.6% completely dropping out of the workforce.

231

232 Evidence on the impact of PCC on the occupational situation and work-related impairments due to PCC is  
233 limited and heterogenous (17–27). Prior studies have reported that between 11% and 50% of individuals  
234 do not return to work (2,14,26) and that 10% to 72% do not fully regain their work capacity 6 to 12 months  
235 after infection (7,23,26,27). Our estimate of 5.8% with occupational changes related to PCC falls in the  
236 lower bound of these estimates, which is likely explained by differences in the evaluated populations (e.g.,  
237 many studies focused on healthcare workers or severely ill patients) and timepoint of assessment (very few  
238 with follow-up six months or longer). Differences between countries in terms of sickness and disability  
239 benefits systems, as well as cultural and organizational factors, may also explain the wide range of estimates  
240 in the literature. Nevertheless, the impact of PCC on the working-age population appears to be substantial  
241 and will likely lead to long-term burdens on economic and healthcare systems.

242

243 An important factor that determines sustainable return to work is the perceived work ability, which is also  
244 more independent of the specific context than return to work and occupational changes. To date, few studies  
245 have evaluated work ability in the context of PCC within specific populations of health-care workers and  
246 patients attending a post COVID-19 clinic (17,22). Evidence from this study and other studies demonstrated  
247 lower work ability scores among those with PCC, with a higher reduction among those with occupational

248 changes. However, it is important to note that although most of the participants with PCC did not have  
249 occupational changes and remained at work, decreased work ability in this group may still indicate reduced  
250 productivity and efficiency. Sickness presenteeism (i.e., continuing to work while sick) may have negative  
251 effects on both the individuals and their employers (48). Sick employees usually need extra efforts to cope  
252 with job demands which may lead to additional worsening of their health, and the costs of having a sick  
253 employee are estimated to be the same as or even higher than their actual absence (48). Strategies that  
254 improve work-related capacity in individuals affected by PCC and promote return to work are urgently  
255 needed. In addition, since reduced work ability also is a predictor of early retirement (38,39), it will be vital  
256 in the coming years to continuously monitor whether there are increases in the number of people retiring  
257 early due to PCC.

258

259 In line with other studies, we found a more substantial decrease in current work ability among individuals  
260 aged 40-64 years compared to younger individuals. This is concerning since the middle-aged population is  
261 typically viewed as the foundation of most economies, as they account for a significant proportion of the  
262 workforce, tax revenue, and gross domestic product. We also found that individuals with a history of  
263 psychiatric diagnosis had a greater reduction in work ability than those without. The relationship between  
264 work and mental health is well-established in the literature (30,49). Targeted strategies and support  
265 measures from occupational and rehabilitation medicine, possibly leveraging pre-existing programs for  
266 individuals with chronic illnesses, should be put in place to support individuals affected by PCC. In  
267 addition, both employees and employers need to be made aware of the mental health aspects of PCC and  
268 the impact of mental health on work, as health-promoting working conditions and, for example, supportive  
269 leadership may be relevant to the re-integration of relevant subgroups of employees (50).

270

271 Fallout from reduced work capacity results not only in financial and health challenges for individuals  
272 affected by PCC, but can also have substantial consequences for the economy and society in the longer  
273 term. Altogether, our findings underline the necessity for interdisciplinary interventions aimed at  
274 individuals affected by PCC, including those with moderate or even mild health impairment. Given that  
275 early intervention is a core principle of occupational rehabilitation, further research is warranted to  
276 determine whether earlier rehabilitation could improve work outcomes in people with persistent symptoms

277 after COVID-19 but who are not yet diagnosed with PCC. Identifying specific COVID-19 symptoms that  
278 predict impairment in work ability will help to develop and provide such early interventions. We consider  
279 this study to be part of that effort.

280

## 281 **Limitations**

282 Strengths of the study include its population-based approach, the large sample size, and the high retention  
283 rate at one year (90%) limiting emigrative selection bias arising from loss to follow-up. In addition, the  
284 granularity of the data and the use of a validated, internationally used, and context-independent measure of  
285 work ability strengthens our evaluation. However, some limitations need to be considered. First,  
286 immigrative selection may have occurred if individuals who were more health literate were more likely to  
287 participate or if individuals who had PCC and more severely impacted were more likely to be retained in  
288 the study. This may have led to an overestimation of the impact of PCC on work ability. In contrast, our  
289 findings may be biased towards lower estimates since only a small proportion of the participants were  
290 hospitalized for COVID-19. Second, the relatively low proportion of hospitalized participants also limits  
291 the generalizability of our results to those with the most severe acute disease, who may also suffer from  
292 more severe medical complications and sequelae of the hospital stay (e.g., post intensive care syndrome).  
293 Additionally, the generalizability of our findings to individuals infected with emerging SARS-CoV-2  
294 variants of concern or who were vaccinated prior to infection is limited, since our participants were all  
295 infected with wildtype SARS-CoV-2 and unvaccinated at infection. The risk of PCC and severe health  
296 impairment is substantially reduced with vaccination and infection with newer variants, but still present  
297 (51–54). As the impact of PCC on work ability is likely comparable in these contexts, this may have  
298 significant socioeconomic implications given that more than 45% of the global population is estimated to  
299 have been infected with the Omicron variant (55). Further research is needed to evaluate whether similar  
300 reduced work ability and occupational changes are observed in vaccinated populations and in the context  
301 of emerging variants of concern. Nonetheless, the population from the early stages of the pandemic included  
302 in this study remains highly relevant since these are the individuals experiencing long-term health  
303 consequences at present, posing a challenge to public health. Third, we assessed PCC using self-reported  
304 measures. Since we could not conduct a clinical validation of PCC, we cannot fully exclude that reported  
305 symptoms and health impairment were related to the presence or worsening of other infections or

306 conditions. Meanwhile, self-reported measures are key for capturing the lived experience of those affected,  
307 and the comparable results across two different definitions of PCC strengthen the credibility of our findings.  
308 Fourth, we did not have data on participants' work ability prior to SARS-CoV-2 infection. Thus, we cannot  
309 be fully certain that the reduced work ability is entirely due to infection and not other preexisting conditions.  
310 However, we at least partially accounted for this in our models by adjusting for baseline health status, and  
311 the detailed evaluation of the individual stories supports our finding of a reduced work ability related to  
312 PCC.

313

### 314 **Conclusion**

315 In this population-based study, we found that PCC significantly reduced the work ability of a relevant  
316 proportion of individuals a year after SARS-CoV-2 infection and in some instances led to an inability to  
317 work altogether. Such loss of productivity and incapacity to work can have severe implications for  
318 individuals, families, and society as a whole. It is critical that policymakers, healthcare professionals, and  
319 employers recognize the impact of PCC on the workforce and develop effective strategies and interventions  
320 that can support and enable affected individuals in regaining and retaining their work ability.

321

322

### 323 **Declarations**

324 **Funding Source:** This study is part of the Corona Immunitas research network, coordinated by the Swiss  
325 School of Public Health (SSPH+), and funded by fundraising of SSPH+ including funds of the Swiss  
326 Federal Office of Public Health and private funders (ethical guidelines for funding stated by SSPH+ were  
327 respected), by funds of the Cantons of Switzerland (Vaud, Zurich, and Basel) and by institutional funds of  
328 the Universities. Additional funding specific to this study was received from the Department of Health of  
329 the Canton of Zurich, the Swiss Federal Office of Public Health, and the University of Zurich (UZH)  
330 Foundation. PK received funding from the Swiss National Science Foundation, grant no [100019M\\_201113](#).  
331 TB received funding from the European Union's Horizon 2020 research and innovation program under the  
332 Marie Skłodowska-Curie grant agreement No 801076, through the SSPH+ Global PhD Fellowship Program  
333 in Public Health Sciences (GlobalP3HS) of the SSPH+. DM received funding by the University of Zurich

334 Postdoc Grant, grant no. FK-22-053. The funding bodies had no influence on the design, conduct, analysis,  
335 interpretation, decision to publish, or reporting of the study.

336

337 **Ethical Approval:** The study was approved by the responsible ethics committee of the Canton of Zurich,  
338 Switzerland (BASEC-Nr. 2020-01739). Written or electronic informed consent was obtained from all  
339 participants.

340

341 **Competing Interests:** The authors declare no conflicts of interest.

342

343 **Author Contributions:** TB, DM, JSF, and MAP conceived and planned the Zurich SARS-CoV-2 Cohort  
344 study. TB, DM, and MAP coordinated the Zurich SARS-CoV-2 Cohort study. PK, TB, MAP, and DM  
345 conceived and designed this analysis. TB, DM, AD, and MAP contributed to participant recruitment and  
346 data collection. MAP supervised the project. JSF and MAP obtained funding. TB and DM prepared the  
347 analytic datasets. DM performed the statistical analysis and SH provided input on the statistical analysis.  
348 All authors contributed to the interpretation of the data. PK, TB, and DM wrote the draft manuscript. All  
349 authors critically revised and provided feedback on the draft manuscript. All authors read and approved the  
350 final manuscript.

351

352 **Acknowledgements:** We thank the study administration team and the study participants for their continued  
353 and highly valuable support.

354

## 355 **References**

- 356 1. Living with Covid19 – Second review [Internet]. NIHR Evidence. 2021 [cited 2022 Jun 16]. Available  
357 from: <https://evidence.nihr.ac.uk/themedreview/living-with-covid19-second-review/>
- 358 2. Nittas V, Gao M, West EA, Ballouz T, Menges D, Wulf Hanson S, et al. Long COVID Through a  
359 Public Health Lens: An Umbrella Review. *Public Health Rev.* 2022 Mar 15;43:1604501.
- 360 3. Global Burden of Disease Long COVID Collaborators. Estimated Global Proportions of Individuals  
361 With Persistent Fatigue, Cognitive, and Respiratory Symptom Clusters Following Symptomatic  
362 COVID-19 in 2020 and 2021. *JAMA.* 2022 Oct 10;
- 363 4. Ballering AV, Zon SKR van, Hartman TC olde, Rosmalen JGM. Persistence of somatic symptoms  
364 after COVID-19 in the Netherlands: an observational cohort study. *The Lancet.* 2022 Aug  
365 6;400(10350):452–61.

- 366 5. Perlis RH, Santillana M, Ognyanova K, Safarpour A, Lunz Trujillo K, Simonson MD, et al. Prevalence  
367 and Correlates of Long COVID Symptoms Among US Adults. *JAMA Network Open*. 2022 Oct  
368 27;5(10):e2238804.
- 369 6. Bull-Otterson L. Post-COVID Conditions Among Adult COVID-19 Survivors Aged 18–64 and ≥65  
370 Years — United States, March 2020–November 2021. *MMWR Morb Mortal Wkly Rep*.  
371 2022;71(21):713–7.
- 372 7. Peter RS, Nieters A, Kräusslich HG, Brockmann SO, Göpel S, Kindle G, et al. Post-acute sequelae of  
373 covid-19 six to 12 months after infection: population based study. *BMJ*. 2022 Oct 13;379:e071050.
- 374 8. Hastie CE, Lowe DJ, McAuley A, Winter AJ, Mills NL, Black C, et al. Outcomes among confirmed  
375 cases and a matched comparison group in the Long-COVID in Scotland study. *Nat Commun*. 2022  
376 Oct 12;13(1):5663.
- 377 9. Menges D, Ballouz T, Anagnostopoulos A, Aschmann HE, Domenghino A, Fehr JS, et al. Burden of  
378 post-COVID-19 syndrome and implications for healthcare service planning: A population-based  
379 cohort study. *PLOS ONE*. 2021 Jul 12;16(7):e0254523.
- 380 10. Ballouz T, Menges D, Anagnostopoulos A, Domenghino A, Aschmann HE, Frei A, et al. Natural  
381 course of post COVID-19 condition and implications for trial design and outcome selection: A  
382 population-based longitudinal cohort study. *medRxiv*. 2022;
- 383 11. Thompson EJ, Williams DM, Walker AJ, Mitchell RE, Niedzwiedz CL, Yang TC, et al. Long COVID  
384 burden and risk factors in 10 UK longitudinal studies and electronic health records. *Nat Commun*.  
385 2022 Jun 28;13(1):3528.
- 386 12. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid—mechanisms, risk factors, and  
387 management. *BMJ*. 2021 Jul 26;374:n1648.
- 388 13. Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and  
389 recommendations. *Nat Rev Microbiol*. 2023 Jan 13;1–14.
- 390 14. Gualano MR, Rossi MF, Borrelli I, Santoro PE, Amantea C, Daniele A, et al. Returning to work and  
391 the impact of post COVID-19 condition: A systematic review. *Work*. 2022 Jan 1;73(2):405–13.
- 392 15. Cutler DM. The Costs of Long COVID. *JAMA Health Forum*. 2022 May 12;3(5):e221809.
- 393 16. Office for National Statistics. Self-reported long COVID and labour market outcomes, UK: 2022  
394 [Internet]. 2023 Dec [cited 2023 Mar 28]. Available from:  
395 [https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/  
396 bulletins/selfreportedlongcovidandlabourmarketoutcomesuk2022/selfreportedlongcovidandlabourma  
397 rketoutcomesuk2022](https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/selfreportedlongcovidandlabourmarketoutcomesuk2022/selfreportedlongcovidandlabourmarketoutcomesuk2022)
- 398 17. Peters C, Dulon M, Westermann C, Kozak A, Nienhaus A. Long-Term Effects of COVID-19 on  
399 Workers in Health and Social Services in Germany. *International Journal of Environmental Research  
400 and Public Health*. 2022 Jan;19(12):6983.
- 401 18. Buonsenso D, Gualano MR, Rossi MF, Valz Gris A, Sisti LG, Borrelli I, et al. Post-Acute COVID-19  
402 Sequelae in a Working Population at One Year Follow-Up: A Wide Range of Impacts from an Italian  
403 Sample. *International Journal of Environmental Research and Public Health*. 2022 Jan;19(17):11093.
- 404 19. Hodgson CL, Higgins AM, Bailey MJ, Mather AM, Beach L, Bellomo R, et al. The impact of COVID-  
405 19 critical illness on new disability, functional outcomes and return to work at 6 months: a prospective  
406 cohort study. *Critical Care*. 2021 Nov 8;25(1):382.
- 407 20. Perlis RH, Lunz Trujillo K, Safarpour A, Santillana M, Ognyanova K, Druckman J, et al. Association  
408 of Post-COVID-19 Condition Symptoms and Employment Status. *JAMA Network Open*. 2023 Feb  
409 15;6(2):e2256152.
- 410 21. Jacobsen PA, Andersen MP, Gislason G, Phelps M, Butt JH, Køber L, et al. Return to work after  
411 COVID-19 infection – A Danish nationwide registry study. *Public Health*. 2022 Feb 1;203:116–22.
- 412 22. Sansone D, Tassinari A, Valentinotti R, Kontogiannis D, Ronchese F, Centonze S, et al. Persistence  
413 of Symptoms 15 Months since COVID-19 Diagnosis: Prevalence, Risk Factors and Residual Work  
414 Ability. *Life*. 2023 Jan;13(1):97.
- 415 23. Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID in  
416 an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine*. 2021 Aug  
417 1;38:101019.



- 418 24. O' Mahony L, Buwalda T, Blair M, Forde B, Lunjani N, Ambikan A, et al. Impact of Long COVID  
419 on health and quality of life. *HRB Open Res.* 2022 Apr 22;5:31.
- 420 25. O'Brien K, Townsend L, Dowds J, Bannan C, Nadarajan P, Kent B, et al. 1-year quality of life and  
421 health-outcomes in patients hospitalised with COVID-19: a longitudinal cohort study. *Respiratory*  
422 *Research.* 2022 May 4;23(1):115.
- 423 26. Vaes AW, Goërtz YMJ, Herck MV, Machado FVC, Meys R, Delbressine JM, et al. Recovery from  
424 COVID-19: a sprint or marathon? 6-month follow-up data from online long COVID-19 support group  
425 members. *ERJ Open Research.* 2021 Apr 1;7(2).
- 426 27. Ziauddeen N, Gurdasani D, O'Hara ME, Hastie C, Roderick P, Yao G, et al. Characteristics and impact  
427 of Long Covid: Findings from an online survey. *PLOS ONE.* 2022 Mar 8;17(3):e0264331.
- 428 28. Cancelliere C, Donovan J, Stochkendahl MJ, Biscardi M, Ammendolia C, Myburgh C, et al. Factors  
429 affecting return to work after injury or illness: best evidence synthesis of systematic reviews. *Chiropr*  
430 *Man Therap.* 2016 Sep 8;24(1):32.
- 431 29. Figueredo JM, García-Ael C, Gragnano A, Topa G. Well-Being at Work after Return to Work (RTW):  
432 A Systematic Review. *International Journal of Environmental Research and Public Health.* 2020  
433 Jan;17(20):7490.
- 434 30. Gragnano A, Negrini A, Miglioretti M, Corbière M. Common Psychosocial Factors Predicting Return  
435 to Work After Common Mental Disorders, Cardiovascular Diseases, and Cancers: A Review of  
436 Reviews Supporting a Cross-Disease Approach. *J Occup Rehabil.* 2018 Jun 1;28(2):215–31.
- 437 31. Ilmarinen J. Work ability—a comprehensive concept for occupational health research and prevention.  
438 *Scandinavian Journal of Work, Environment & Health.* 2009;35(1):1–5.
- 439 32. van den Berg TIJ, Elders L a. M, Zwart BCH de, Burdorf A. The effects of work-related and individual  
440 factors on the Work Ability Index: a systematic review. *Occupational and Environmental Medicine.*  
441 2009 Apr 1;66(4):211–20.
- 442 33. Tuomi K, Ilmarinen J, Jahkola A, Katajarinne L, Tulkki A. Work Ability Index. Finnish institute of  
443 occupational health. 1997;19.
- 444 34. Ahlstrom L, Grimby-Ekman A, Hagberg M, Dellve L. The work ability index and single-item question:  
445 associations with sick leave, symptoms, and health – a prospective study of women on long-term sick  
446 leave. *Scandinavian Journal of Work, Environment & Health.* 2010;36(5):404–12.
- 447 35. Kujala V, Tammelin T, Remes J, Vammavaara E, Ek E, Laitinen J. Work ability index of young  
448 employees and their sickness absence during the following year. *Scandinavian Journal of Work,*  
449 *Environment & Health.* 2006;32(1):75–84.
- 450 36. Kinnunen U, Nätti J. Work ability score and future work ability as predictors of register-based  
451 disability pension and long-term sickness absence: A three-year follow-up study. *Scand J Public*  
452 *Health.* 2018 May 1;46(3):321–30.
- 453 37. Gustafsson K, Marklund S. Consequences of sickness presence and sickness absence on health and  
454 work ability: A Swedish prospective cohort study. *IJOMEH.* 2011 Jun 1;24(2):153–65.
- 455 38. van den Berg TIJ, Elders LAM, Bürdorf A. Influence of Health and Work on Early Retirement. *Journal*  
456 *of Occupational and Environmental Medicine.* 2010;52(6):576–83.
- 457 39. Sell L. Predicting long-term sickness absence and early retirement pension from self-reported work  
458 ability. *Int Arch Occup Environ Health.* 2009 Oct 1;82(9):1133–8.
- 459 40. Alavinia SM, de Boer AGEM, van Duivenbooden JC, Frings-Dresen MHW, Burdorf A. Determinants  
460 of work ability and its predictive value for disability. *Occupational Medicine.* 2009 Jan 1;59(1):32–7.
- 461 41. ISRCTN14990068: Zurich Coronavirus Cohort: an observational study to determine long-term clinical  
462 outcomes and immune responses after coronavirus infection (COVID-19), assess the influence of virus  
463 genetics, and examine the spread of the coronavirus in the population of the Canton of Zurich,  
464 Switzerland. ISRCTN Registry. 2020;
- 465 42. Central Compensation Office. Old-age pensions [Internet]. [cited 2023 Mar 28]. Available from:  
466 <https://www.zas.admin.ch/zas/en/home/particuliers/rentes-de-vieillesse.html>

- 467 43. von Bonsdorff MB, Seitsamo J, Ilmarinen J, Nygård CH, von Bonsdorff ME, Rantanen T. Work ability  
468 in midlife as a predictor of mortality and disability in later life: a 28-year prospective follow-up study.  
469 *CMAJ*. 2011 Mar 8;183(4):E235–42.
- 470 44. Perneger TV, Combescure C, Courvoisier DS. General Population Reference Values for the French  
471 Version of the EuroQol EQ-5D Health Utility Instrument. *Value in Health*. 2010 Jul;13(5):631–5.
- 472 45. Zanini A, Aiello M, Adamo D, Casale S, Cherubino F, Patrona SD, et al. Estimation of Minimal  
473 Clinically Important Difference in EQ-5D Visual Analog Scale Score After Pulmonary Rehabilitation  
474 in Subjects With COPD. *Respiratory Care*. 2015 Jan 1;60(1):88–95.
- 475 46. Wacker ME, Jörres RA, Karch A, Wilke S, Heinrich J, Karrasch S, et al. Assessing health-related  
476 quality of life in COPD: comparing generic and disease-specific instruments with focus on  
477 comorbidities. *BMC Pulmonary Medicine*. 2016 May 10;16(1):70.
- 478 47. R Core Team. R: a language and environment for statistical computing [Internet]. 2018 [cited 2021  
479 Nov 19]. Available from: [Http://www.r-project.org/](http://www.r-project.org/)
- 480 48. Kinman G. Sickness presenteeism at work: prevalence, costs and management. 2019 Jan 11;
- 481 49. van den Berg S, Burdorf A, Robroek SJW. Associations between common diseases and work ability  
482 and sick leave among health care workers. *Int Arch Occup Environ Health*. 2017 Oct 1;90(7):685–93.
- 483 50. Bavel JJV, Baicker K, Boggio PS, Capraro V, Cichocka A, Cikara M, et al. Using social and  
484 behavioural science to support COVID-19 pandemic response. *Nat Hum Behav*. 2020 May;4(5):460–  
485 71.
- 486 51. Ballouz T, Menges D, Kaufmann M, Amati R, Frei A, Wyl V von, et al. Post COVID-19 condition  
487 after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: Pooled analysis of  
488 two population-based cohorts. *PLOS ONE*. 2023 Feb 22;18(2):e0281429.
- 489 52. Azzolini E, Levi R, Sarti R, Pozzi C, Mollura M, Mantovani A, et al. Association Between BNT162b2  
490 Vaccination and Long COVID After Infections Not Requiring Hospitalization in Health Care Workers.  
491 *JAMA*. 2022 Aug 16;328(7):676–8.
- 492 53. Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, et al. Impact of COVID-19  
493 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: A  
494 systematic review. *eClinicalMedicine*. 2022 Nov 1;53:101624.
- 495 54. Antonelli M, Pujol JC, Spector TD, Ourselin S, Steves CJ. Risk of long COVID associated with delta  
496 versus omicron variants of SARS-CoV-2. *The Lancet*. 2022 Jun 18;399(10343):2263–4.
- 497 55. COVID-19 Forecasting Team. Forecasting the trajectory of the COVID-19 pandemic into 2023 under  
498 plausible variant and intervention scenarios: a global modelling study [Internet]. Institute for Health  
499 Metrics and Evaluation. 2023 [cited 2023 Mar 28]. Available from:  
500 [https://www.healthdata.org/research-article/forecasting-trajectory-covid-19-pandemic-2023-under-](https://www.healthdata.org/research-article/forecasting-trajectory-covid-19-pandemic-2023-under-plausible-variant-and)  
501 [plausible-variant-and](https://www.healthdata.org/research-article/forecasting-trajectory-covid-19-pandemic-2023-under-plausible-variant-and)
- 502
- 503
- 504



505 **Tables & Figures**

506 **Table 1: Study participant characteristics.**

	<b>Overall (N=672)</b>
<b>Age (years)</b>	
Mean (SD)	42.1 (12.2)
Median (IQR)	43.0 (31.0 to 53.0)
Range	18 to 63
<b>Age group</b>	
18-39 years	282 (42.0%)
40-64 years	390 (58.0%)
<b>Sex</b>	
female	364 (54.2%)
male	308 (45.8%)
<b>Symptom count at infection</b>	
Asymptomatic	79 (11.8%)
1-5 symptoms	266 (39.6%)
≥6 symptoms	327 (48.7%)
<b>Hospitalization at infection</b>	
Non-hospitalized	662 (98.5%)
Hospitalized	9 (1.3%)
with ICU stay	1 (0.1%)
<b>Smoking status</b>	
Non-smoker	413 (61.6%)
Ex-smoker	156 (23.3%)
Smoker	101 (15.1%)
<i>Missing</i>	2 (0.3%)
<b>BMI (kg/sqm)</b>	
Mean (SD)	24.4 (4.5)
Median (IQR)	23.7 (21.5 to 26.2)
Range	13 to 63
<i>Missing</i>	6 (0.9%)
<b>Comorbidity*</b>	
None	532 (79.2%)
1 comorbidity	113 (16.8%)
≥2 comorbidities	27 (4.0%)
<b>History of psychiatric diagnosis</b>	
None	565 (86.8%)
Any	86 (13.2%)
<i>Missing</i>	21 (3.1%)

**Education level**

None or mandatory school	22 (3.3%)
Vocational training or specialized baccalaureate	249 (37.2%)
Higher technical school or college	194 (29.0%)
University	205 (30.6%)
<i>Missing</i>	2 (0.3%)

**Employment at infection**

Employed or self-employed	587 (87.4%)
Student	46 (6.8%)
Housewife/family manager	10 (1.5%)
Unemployed	19 (2.8%)
Disability insurance benefits	4 (0.6%)
Other	6 (0.9%)

**Income**

<6'000 CHF	189 (29.2%)
6'000 - 12'000 CHF	283 (43.7%)
>12'000 CHF	176 (27.2%)
<i>Missing</i>	24 (3.6%)

**Nationality**

Swiss	562 (83.6%)
Non-Swiss	110 (16.4%)

507 Legend: BMI, body mass index; CHF, Swiss Francs; ICU, intensive care unit; IQR, interquartile range; SD,  
508 standard deviation. \* Comorbidities were assessed as any of the following: hypertension, diabetes,  
509 cardiovascular disease, chronic respiratory disease, chronic kidney disease, past or present malignancy, or  
510 immune suppression.

511 **Table 2: Results from multivariable regression analyses for the association of post COVID-19 condition (PCC, defined as presence of COVID-19 related**  
 512 **symptoms) with work ability outcomes (PCC vs. no PCC) within subgroups based on sex, age group, comorbidity count, or history of psychiatric diagnosis.**

Interaction	Current work ability		Physical demands		Mental demands		Future (2 years)	
	Estimate (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
<b>Male vs. female</b>								
Female	-0.82 (-1.23 to -0.42)	<0.001	0.37 (0.22 to 0.62)	<0.001	0.40 (0.23 to 0.67)	<0.001	0.54 (0.23 to 1.27)	0.159
Male	-0.30 (-0.81 to 0.21)	0.254	0.22 (0.11 to 0.43)	<0.001	0.42 (0.22 to 0.81)	0.009	0.48 (0.14 to 1.64)	0.243
<i>Difference*</i>	<i>0.53 (-0.12 to 1.17)</i>	<i>0.106</i>	<i>0.60 (0.26 to 1.38)</i>	<i>0.229</i>	<i>1.06 (0.46 to 2.42)</i>	<i>0.894</i>	<i>0.89 (0.21 to 3.88)</i>	<i>0.881</i>
<b>40-64 years vs. 18-39 years</b>								
18-39 years	-0.27 (-0.86 to 0.32)	0.372	0.74 (0.33 to 1.65)	0.460	0.69 (0.33 to 1.44)	0.322	0.93 (0.19 to 4.45)	0.924
40-64 years	-0.78 (-1.16 to -0.40)	<0.001	0.20 (0.12 to 0.34)	<0.001	0.33 (0.20 to 0.55)	<0.001	0.43 (0.19 to 0.96)	0.040
<i>Difference*</i>	<i>-0.51 (-1.20 to 0.19)</i>	<i>0.149</i>	<i>0.27 (0.11 to 0.71)</i>	<i>0.006</i>	<i>0.48 (0.20 to 1.17)</i>	<i>0.107</i>	<i>0.46 (0.08 to 2.67)</i>	<i>0.369</i>
<b>≥2 comorbidities vs. 0-1 comorbidity<sup>†</sup></b>								
0-1 comorbidity	-0.64 (-0.97 to -0.31)	<0.001	0.31 (0.20 to 0.47)	<0.001	0.39 (0.26 to 0.60)	<0.001	0.46 (0.22 to 0.96)	0.040
≥2 comorbidities	-0.92 (-2.34 to 0.50)	0.202	0.10 (0.01 to 0.79)	0.028	0.52 (0.08 to 3.34)	0.490	1.19 (0.10 to 14.80)	0.894
<i>Difference*</i>	<i>-0.28 (-1.74 to 1.18)</i>	<i>0.702</i>	<i>0.34 (0.04 to 2.67)</i>	<i>0.308</i>	<i>1.32 (0.20 to 8.90)</i>	<i>0.776</i>	<i>2.59 (0.19 to 36.17)</i>	<i>0.462</i>
<b>History of psychiatric diagnosis vs. no history of psychiatric diagnosis</b>								
No history of psychiatric diagnosis	-0.39 (-0.74 to -0.04)	0.031	0.28 (0.17 to 0.44)	<0.001	0.35 (0.22 to 0.55)	<0.001	0.49 (0.22 to 1.08)	0.077
History of psychiatric diagnosis	-1.73 (-2.47 to -0.99)	<0.001	0.49 (0.18 to 1.31)	0.155	0.88 (0.33 to 2.35)	0.803	0.65 (0.15 to 2.76)	0.563
<i>Difference*</i>	<i>-1.34 (-2.15 to -0.53)</i>	<i>0.001</i>	<i>1.76 (0.60 to 5.00)</i>	<i>0.303</i>	<i>2.55 (0.88 to 7.25)</i>	<i>0.086</i>	<i>1.33 (0.27 to 6.67)</i>	<i>0.725</i>

0.54)

5.17)

7.38)

---

513 Legend: CI, confidence interval; OR, odds ratio. \* P-values for differences calculated using likelihood ratio test for models with and without interaction term for the  
514 respective stratification variable. Models are multivariable linear regression models (current work ability) or multivariable ordinal logistic regression models (work ability  
515 related to physical and mental demands, estimated future work ability in 2 years) including an interaction term for the respective stratification variable and adjusted for  
516 age (or age group for the corresponding analysis), sex, education status, baseline EuroQol visual analog scale (EQ-VAS), comorbidity count (as a continuous variable,  
517 or as a categorical variable for the corresponding analysis), history of psychiatric diagnosis, and hospitalization due to COVID-19. † Comorbidities were assessed as any  
518 of the following: hypertension, diabetes, cardiovascular disease, chronic respiratory disease, chronic kidney disease, past or present malignancy, or immune suppression.  
519  
520

521 **Table 3: Occupational changes related to post COVID-19 condition and overall, stratified by post COVID-19 condition and (non-)recovery and health**  
522 **impairment status.**


	PCC status		(Non-)recovery and health impairment status				Overall (N=672)
	No PCC (N=552)	PCC (N=120)	Recovered (N=562)	Mild (N=72)	Moderate (N=13)	Severe (N=8)	
<b>Occupational change</b>							
No occupational change	451 (83.7%)	89 (74.2%)	468 (83.9%)	58 (80.6%)	6 (46.2%)	3 (37.5%)	540 (81.9%)
Occupational change unrelated to PCC	88 (16.3%)	24 (20.0%)	90 (16.1%)	13 (18.1%)	4 (30.8%)	3 (37.5%)	112 (17.0%)
Occupational change related to PCC	0 (0.0%)	7 (5.8%)	0 (0.0%)	1 (1.4%)	3 (23.1%)	2 (25.0%)	7 (1.1%)
<i>Missing</i>	13 (2.4%)	0 (0%)	4 (0.7%)	0 (0%)	0 (0%)	0 (0%)	13 (1.9%)
<b>Reason for occupational change*</b>							
Retired	4 (4.6%)	2 (6.5%)	5 (5.6%)	0 (0.0%)	0 (0.0%)	1 (20.0%)	6 (5.1%)
On permanent sick leave	3 (3.4%)	1 (3.2%)	2 (2.2%)	0 (0.0%)	1 (14.3%)	0 (0.0%)	4 (3.4%)
Receiving disability benefits	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	1 (14.3%)	0 (0.0%)	1 (0.8%)
Work leave for different reason	3 (3.4%)	0 (0.0%)	3 (3.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	3 (2.5%)
Newly self-employed	2 (2.3%)	0 (0.0%)	2 (2.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.7%)
Changed workplace	42 (48.3%)	14 (45.2%)	46 (51.7%)	7 (50.0%)	3 (42.9%)	0 (0.0%)	56 (47.5%)
Changed position within same workplace	13 (14.9%)	4 (12.9%)	11 (12.4%)	4 (28.6%)	0 (0.0%)	1 (20.0%)	17 (14.4%)
Started training or university studies	5 (5.7%)	0 (0.0%)	4 (4.5%)	1 (7.1%)	0 (0.0%)	0 (0.0%)	5 (4.2%)
Reduced working hours	2 (2.3%)	0 (0.0%)	2 (2.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	2 (1.7%)
Lost employment	4 (4.6%)	2 (6.5%)	5 (5.6%)	0 (0.0%)	1 (14.3%)	0 (0.0%)	6 (5.1%)
Other	9 (10.3%)	7 (22.6%)	9 (10.1%)	2 (14.3%)	1 (14.3%)	3 (60.0%)	16 (13.6%)
<i>Missing</i>	1 (1.1%)	0 (0%)	1 (1.1%)	0 (0%)	0 (0%)	0 (0%)	1 (0.8%)
<b>Financial difficulties due to occupational change*</b>							
No	57 (64.8%)	17 (54.8%)	56 (62.2%)	10 (71.4%)	4 (57.1%)	3 (60.0%)	74 (62.2%)

Rather not	12 (13.6%)	6 (19.4%)	15 (16.7%)	3 (21.4%)	0 (0.0%)	0 (0.0%)	18 (15.1%)
Yes, a little	14 (15.9%)	7 (22.6%)	15 (16.7%)	1 (7.1%)	3 (42.9%)	1 (20.0%)	21 (17.6%)
Yes, very much	5 (5.7%)	0 (0.0%)	4 (4.4%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	5 (4.2%)
Unclear/no answer	0 (0.0%)	1 (3.2%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	1 (20.0%)	1 (0.8%)

523 Legend: PCC, post COVID-19 condition. \* Percentages calculated within total of individuals with any occupational change (N=119).

524


525 **Figure 1: Flow chart of participant enrollment and inclusion in this study.**



526

527

528 **Figure 2: Current work ability, work ability related to physical and mental demands, and estimated**  
 529 **future work ability in 2 years by presence of post COVID-19 condition and non-recovery and health**  
 530 **impairment at 12 months after diagnosis of primary infection.** Panels A–D demonstrate the level of  
 531 current work ability (A), work ability related to physical (B) and mental (C) demands, and estimated work  
 532 ability in 2 years (D) between individuals with post COVID-19 condition (PCC)-related symptoms at 12  
 533 months compared to those without PCC. Panels E–H show the level of current work ability (E), work ability  
 534 related to physical (F) and mental (G) demands, and estimated work ability in 2 years (H) between  
 535 individuals reporting non-recovery with mild, moderate, or severe health impairment at 12 months  
 536 compared to those reporting full recovery at 12 months. Legend: PCC, post COVID-19 condition; WAI,  
 537 work ability index.




538

539



540 **Figure 3: Results from multivariable regression analyses of the association between presence of post**  
 541 **COVID-19 condition and current work ability, work ability related to physical and mental demands,**  
 542 **and estimated future work ability in 2 years at 12 months after diagnosis of primary infection.** Each  
 543 panel demonstrates results from multivariable linear regression (current work ability) or ordinal logistic  
 544 regression (work ability related to physical and mental demands, estimated work ability in future) adjusted  
 545 for sex, age, education level, baseline EuroQol visual analog scale (EQ-VAS), comorbidity count, history  
 546 of psychiatric diagnosis, and hospitalization at acute infection. Separate models were estimated for the two  
 547 definitions based on COVID-19 related symptoms (PCC vs. no PCC) and (non-)recovery (severe, moderate  
 548 or mild health impairment vs. recovery). Legend: CI, confidence interval; OR, odds ratio; PCC, post  
 549 COVID-19 condition; Ref., reference.



550